CRIS Current Research Information System

GUGLIOTTA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.960
NA - Nord America 5.783
EU - Europa 3.979
SA - Sud America 364
AF - Africa 330
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.432
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.731
VN - Vietnam 1.710
SG - Singapore 1.599
CN - Cina 1.488
GB - Regno Unito 1.165
IT - Italia 503
DE - Germania 483
SE - Svezia 476
HK - Hong Kong 345
NL - Olanda 294
BR - Brasile 262
FR - Francia 258
IN - India 255
RU - Federazione Russa 218
KR - Corea 144
IE - Irlanda 141
UA - Ucraina 109
JP - Giappone 106
ZA - Sudafrica 95
TG - Togo 82
EE - Estonia 72
FI - Finlandia 62
CI - Costa d'Avorio 56
JO - Giordania 51
BG - Bulgaria 50
NG - Nigeria 38
AR - Argentina 35
PH - Filippine 34
CH - Svizzera 32
CA - Canada 30
ID - Indonesia 30
TH - Thailandia 28
BD - Bangladesh 27
IQ - Iraq 27
AT - Austria 26
BE - Belgio 25
SC - Seychelles 21
PL - Polonia 18
EC - Ecuador 17
IR - Iran 17
MX - Messico 16
TW - Taiwan 16
PK - Pakistan 14
TR - Turchia 14
AU - Australia 13
CL - Cile 12
ES - Italia 11
VE - Venezuela 11
CO - Colombia 9
UZ - Uzbekistan 9
IL - Israele 7
MA - Marocco 7
SA - Arabia Saudita 7
LB - Libano 6
MY - Malesia 6
PE - Perù 6
PY - Paraguay 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
GR - Grecia 5
KE - Kenya 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
EG - Egitto 4
ET - Etiopia 4
LT - Lituania 4
NO - Norvegia 4
UY - Uruguay 4
NP - Nepal 3
AL - Albania 2
AZ - Azerbaigian 2
DZ - Algeria 2
GE - Georgia 2
GM - Gambi 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
AO - Angola 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
EU - Europa 1
JM - Giamaica 1
KW - Kuwait 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LV - Lettonia 1
LY - Libia 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TT - Trinidad e Tobago 1
Totale 16.430
Salva come PNG Salva come JPEG
Città #
Singapore 1.139
Southend 1.072
Ashburn 662
Fairfield 606
Chandler 473
Ho Chi Minh City 397
Hanoi 367
San Jose 327
Hong Kong 323
Woodbridge 298
Wilmington 295
Houston 289
Hefei 277
Seattle 276
Beijing 236
Dong Ket 226
Cambridge 220
Princeton 201
Ann Arbor 170
Dublin 141
Boardman 133
Seoul 125
Bologna 114
Lauterbourg 108
Nanjing 102
Santa Clara 102
Tokyo 87
Westminster 83
Lomé 82
Padova 71
Los Angeles 70
New York 69
Berlin 64
Abidjan 56
Haiphong 54
Helsinki 52
Da Nang 51
Jinan 50
Sofia 50
Dallas 49
Amman 48
Buffalo 48
Shenyang 45
Milan 44
Redondo Beach 42
Frankfurt am Main 41
Jacksonville 39
Abeokuta 37
Changsha 37
Turin 34
Saint Petersburg 33
Bengaluru 31
Nanchang 28
Bern 27
San Diego 27
Shanghai 27
São Paulo 27
Tianjin 27
Biên Hòa 26
Guangzhou 25
Medford 25
Brussels 24
Falls Church 24
Redmond 24
Jiaxing 23
Munich 22
Nuremberg 22
Zhengzhou 22
Council Bluffs 21
Des Moines 21
Hebei 21
The Dalles 20
Bremen 19
Mountain View 18
Rome 18
London 17
Norwalk 17
Chengdu 16
Hangzhou 16
Orem 16
Baghdad 15
Chicago 15
Dearborn 15
Warsaw 15
Can Tho 14
Hải Dương 14
Ninh Bình 14
Phoenix 14
Boston 13
Bắc Ninh 13
Falkenstein 13
Ha Long 13
Jakarta 13
Taizhou 13
Haikou 12
Ningbo 12
Bắc Giang 11
Bến Tre 11
Montreal 11
Paris 11
Totale 10.928
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 385
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 343
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 272
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 251
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 226
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 224
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 220
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 219
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 219
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 218
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 199
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 199
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study 196
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 195
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 194
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 189
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 188
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 188
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 186
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 184
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 183
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 182
A review of the European LeukemiaNet recommendations for the management of CML 179
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 173
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 171
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 166
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 166
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 165
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 164
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 161
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 160
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 159
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 158
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 157
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 153
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 152
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 151
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 151
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 150
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 150
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 150
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 149
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 147
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 145
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 145
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 144
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 144
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 143
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 141
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Diagnosis and classification of the risk 140
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 138
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia 138
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 138
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 138
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 137
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 136
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 134
Essential role of lyn in fibrosis 131
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 129
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 129
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 129
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 126
First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies 124
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 124
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 123
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials 122
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 122
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 121
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 121
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 120
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 120
Safety profiles of first-line TKIS and managing adverse effects 118
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study 116
Current treatment approaches in CML. 115
Differences among young adults, adults and elderly chronic myeloid leukemia patients 115
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 115
EARLY PREDICTORS OF PROGRESSION TO ACCELERATED-BLASTIC PHASE IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 114
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML 113
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 110
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 110
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase 110
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 110
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 106
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 104
EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS 103
Thyrosin kinase inhibitors: nilotinib 97
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 94
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 93
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools 92
Totale 15.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.671
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021614 0 0 0 0 0 0 0 0 0 60 150 404
2021/20221.674 153 57 137 140 170 99 27 97 83 103 286 322
2022/20231.961 198 299 107 240 156 140 87 122 341 35 159 77
2023/2024507 27 83 36 55 47 116 25 19 23 32 18 26
2024/20252.352 66 357 205 164 267 106 148 63 32 366 119 459
2025/20265.536 696 667 532 445 569 288 556 278 1.132 373 0 0
Totale 16.765